Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PRTG
Upturn stock ratingUpturn stock rating

Portage Biotech Inc (PRTG)

Upturn stock ratingUpturn stock rating
$4.37
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/10/2025: PRTG (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -71.87%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/10/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.72M USD
Price to earnings Ratio -
1Y Target Price 140
Price to earnings Ratio -
1Y Target Price 140
Volume (30-day avg) 1308991
Beta 99.48
52 Weeks Range 2.10 - 25.15
Updated Date 01/15/2025
52 Weeks Range 2.10 - 25.15
Updated Date 01/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -68.17

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -19.42%
Return on Equity (TTM) -191.03%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2983658
Price to Sales(TTM) -
Enterprise Value 2983658
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.02
Shares Outstanding 1121060
Shares Floating 595206
Shares Outstanding 1121060
Shares Floating 595206
Percent Insiders 29.81
Percent Institutions 17.8

AI Summary

Portage Biotech Inc.: A Comprehensive Overview

Company Profile

History and Background:

Portage Biotech Inc. (PRTG), formerly known as Portage Pharmaceuticals, Inc., was founded in 2011 in Ann Arbor, Michigan. Initially, the company focused on developing novel pharmaceuticals for the treatment of gastrointestinal diseases. In 2016, Portage shifted its focus to developing RNA-based therapeutics for diseases with large unmet medical needs. This shift came after positive preclinical data for their lead candidate, PGT-301, in Friedreich's Ataxia.

Core Business Areas:

Currently, Portage Biotech is primarily focused on the discovery and development of novel RNA-based therapies. This includes:

  • Small interfering RNA (siRNA): SiRNA molecules are designed to silence specific genes involved in disease pathogenesis. Portage is exploring siRNA therapies for Friedreich's Ataxia, Amyotrophic Lateral Sclerosis (ALS), and other neurological disorders.
  • MicroRNA (miRNA): miRNA molecules regulate gene expression and can be used to restore or silence the expression of specific genes. Portage is exploring miRNA therapies for Duchenne Muscular Dystrophy (DMD) and other neuromuscular disorders.

Leadership and Corporate Structure:

  • CEO: Dr. Ian Walters: Extensive experience in the pharmaceutical industry, having held leadership positions at several major companies.
  • President & COO: Dr. Mark McCamish: Proven track record in developing and commercializing pharmaceutical products.
  • CFO & Treasurer: Brian Markison: Strong financial expertise & experience in managing public companies.

Top Products and Market Share:

Portage's development pipeline currently consists of two lead candidates:

  • PGT-301: A siRNA therapy for Friedreich's Ataxia. It is currently in a Phase 3 clinical trial.
  • PRG-342: A miRNA therapy for DMD. It is currently in a Phase 1b/2a clinical trial.

Neither PGT-301 nor PRG-342 are commercially available yet; therefore, they have no current market share.

Competitive Landscape:

Portage competes with several other companies developing RNA-based therapies. Key competitors include Arrowhead Pharmaceuticals (ARWR), Dicerna Pharmaceuticals (DRNA), and Akcea Therapeutics (AKCA).

  • Portage: Strong preclinical data and promising clinical progress for both PGT-301 and PRG-342.
  • Arrowhead Pharmaceuticals: More advanced clinical pipeline with multiple ongoing Phase 3 trials.
  • Dicerna Pharmaceuticals: Strong technology platform and several drug candidates in Phase 2 development.
  • Akcea Therapeutics: First approved RNA-based therapy for a rare genetic disease (Tegsedi), established commercial presence.

Total Addressable Market

The global market for RNA-based therapies is estimated to reach $15 billion by 2025. The specific markets for Friedreich's Ataxia, ALS, DMD, and other diseases targeted by Portage are estimated to be in the hundreds of millions of dollars.

Financial Performance

Portage is currently in the development stage and has not yet generated any revenue from product sales. However, the company has reported increasing net losses in recent years due to ongoing clinical trials and research & development activities.

Dividends and Shareholder Returns

Portage is currently not paying any dividends and focuses on reinvesting its resources in R&D and clinical development.

Growth Trajectory

Portage has shown strong growth in its operations and clinical development programs in recent years. Key milestones include:

  • Completion of Phase 2 clinical trial for PGT-301 in Friedreich's Ataxia.
  • Initiation of Phase 3 clinical trial for PGT-301 in Friedreich's Ataxia.
  • Completion of Phase 1b and initiation of Phase 2 clinical trial for PRG-342 in DMD.

Portage's future growth will depend on the success of its clinical trials and potential commercialization of its therapies.

Market Dynamics

The RNA-based therapeutics market is rapidly growing, driven by advancements in technology and increasing recognition of the potential of these therapies to treat serious diseases. However, competition is intensifying, and regulatory approvals remain a key challenge.

Key Challenges and Opportunities

: Key Challenges:

  • Clinical Trial Success: Portage's future success relies heavily on the successful completion of ongoing clinical trials and regulatory approval of its therapies.
  • Competition: Intense competition from other companies developing RNA-based therapies for similar indications.
  • Financing: Portage will need to raise additional capital to fund its ongoing clinical trials and commercialization efforts.

Opportunities:

  • Portage's therapies target large unmet medical needs with significant market potential.
  • Positive clinical data and successful commercialization could lead to substantial shareholder value creation.
  • Partnerships with larger pharmaceutical companies could provide additional financial resources and development expertise.

Recent Acquisitions (last 3 years)

Portage Biotech has not made any acquisitions in the last three years.

AI-Based Fundamental Rating

Based on publicly available data and an AI-based analysis model, Portage Biotech Inc. receives a fundamental rating of 5.5 out of 10.

Reasons for this rating:

  • Positives: Promising pipeline with two late-stage clinical candidates, strong leadership team, large addressable market.
  • Negatives: No current revenue, significant operating losses, high clinical development risk.

Sources and Disclaimers

This overview is based on information obtained from the following sources:

I hope this comprehensive overview of Portage Biotech Inc. is helpful. Please let me know if you have any further questions.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-02-25
CEO & Chairman of Board Dr. Ian B. Walters M.B.A., M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 7
Full time employees 7

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​